Blog
RSS FeedPosted by Michael Wonder on 08 Feb 2019
Number needed to treat: conveying the likelihood of a therapeutic effect
7 February 2019 - Effectively communicating clinical trial results to patients and clinicians is a requirement for appropriate application in ...
Posted by Michael Wonder on 14 Sep 2018
EMA Priority Medicines scheme (PRIME): will more paying-for-performance agreements be needed due to immature data?
14 September 2018 - The EU’s centralized procedure for the authorization of a new drug is performed by the EMA. ...
Posted by Michael Wonder on 28 Aug 2018
Data enclaves for sharing information derived from clinical and administrative data
28 August 2018 - The promise that big data will transform health care has yet to be fulfilled. ...
Posted by Michael Wonder on 14 Aug 2018
Tech giants pledge to ease patient, provider access to health data
13 August 2018 - Promise seen as opportunity to bring on data-driven revolution in health care. ...
Posted by Michael Wonder on 11 Aug 2018
IBM bet billions that Watson could improve cancer treatment. It hasn’t worked.
11 August 2018 - Big Blue’s Watson artificial intelligence product sometimes didn’t say more than doctors already knew. ...
Posted by Michael Wonder on 16 Jul 2018
EMA’s proactive publication of clinical data a success
16 July 2018 - First report on unprecedented transparency policy shows high user satisfaction. ...
Posted by Michael Wonder on 13 Jul 2018
Health Canada ordered to release confidential drug company data on HPV vaccines
13 July 2018 - Federal government insisted drug companies' clinical trial data is 'confidential business information'. ...
Posted by Michael Wonder on 27 Jun 2018
Gottlieb calls on payers to share data to aid drug innovation
25 June 2018 - The FDA is working to modernize the clinical trial process in order to answer the right ...
Posted by Michael Wonder on 06 Jun 2018
Clinical trial participants’ views of the risks and benefits of data sharing
7 June 2018 - Sharing of participant-level clinical trial data has potential benefits, but concerns about potential harms to research participants ...
Posted by Michael Wonder on 07 May 2018
Understanding statistical principles in linear and logistic regression
7 May 2018 - A previous article in this series assessed the association between two variables. Here, we introduce the concept ...
Posted by Michael Wonder on 18 Apr 2018
Post-marketing modifications of drug labels for cancer drugs approved by the US FDA between 2006 and 2016 with and without supporting randomized controlled trials
11 April 2018 - Modifications in cancer drug indications, dosing, and related toxicities after FDA approval are common. It is unclear ...
Posted by Michael Wonder on 01 Feb 2018
A revolution in health care is coming
1 February 2018 - Welcome to Doctor you. ...
Posted by Michael Wonder on 29 Nov 2017
Is the FDA withholding data about a controversial drug to protect its manufacturer?
29 November 2017 - In the case of Sarepta, it sure looks that way. ...
Posted by Michael Wonder on 20 Nov 2017
Use of health care databases to support supplemental indications of approved medications
20 November 2017 - Can health care databases be used to confirm a supplemental indication that has been demonstrated in a ...
Posted by Michael Wonder on 20 Oct 2017
Unparalleled access to clinical data - one year on
20 October 2017 - Over 3,000 clinical documents published, 3,600 registered users and positive stakeholder feedback. ...